The peptide rush is on. Is a new category forming?

By Peptide Policy Watch staff · Published November 11, 2026 · 8 min read · 11 sources, 9 checked at the source

AI-generated editorial illustration: three adults in workout clothes smile in a bright gym lounge, holding water bottles, with a row of small bottles on a low shelf in the foreground.

The peptide rush is on.

Is a new category forming between supplements and prescription drugs? Two weeks ago, the six peptides in HHS's draft compounding policy were names you mostly heard in gyms and group chats. Now public companies are lining up to offer them.

Here's what they have actually put in writing. Enhanced Group, the company behind the Enhanced Games, says its Live Enhanced telehealth platform began offering all six of those peptides (BPC-157, TB-500, semax, epitalon, MOTS-c and KPV) on November 3, by prescription only, six days after HHS announced the policy. [V] Hims & Hers says its Peptides+ launch comes later this month. [S] DataMEDS AI, a Nasdaq-listed pharmacy company, says its Corexa Pharmacy has already logged a first sale of one of the six. [V]

Who's moving fastest? That's what the scoreboard below is for: each company's own words, with the date and the document behind the line.

Facts are as of November 11, 2026. Sources, with retrieval dates, are at the bottom.

The scoreboard, in one glance

Enhanced (NYSE: ENHA) says all six HHS peptides went live on its Live Enhanced platform on November 3, prescription only, alongside the GHK-Cu and sermorelin it already offered. [V]
Hims & Hers previewed Peptides+ on October 29 and told investors on November 9 that the first phase starts later this month with sermorelin, glutathione and NAD. BPC-157 and TB-500 wait for the rules. [V] [S]
DataMEDS AI (Nasdaq: MEDS) says its Corexa Pharmacy sold its first compounded peptide from the HHS list on November 9, without naming which one. [V]
Public comments on the HHS draft close at 11:59 PM Eastern on Thursday, November 13. [V]

Who has announced what

Company	What it says	Date	The six HHS peptides?	Source
Enhanced Group	Offering all six now, by prescription, through Live Enhanced	Nov. 3, 2026	Yes, all six, per its release [V]	Company release
Hims & Hers	Peptides+ preview; sermorelin, glutathione, B12, NAD+ and L-carnitine planned	Oct. 29, 2026	BPC-157 and TB-500 "when allowable" [V]	Hims newsroom
Hims & Hers	First phase later this month: sermorelin, glutathione, NAD	Nov. 9, 2026	Not yet; waiting on the regulatory picture [S]	Earnings call
DataMEDS AI / Corexa Pharmacy	A first commercial sale from the six-peptide list	Nov. 9, 2026	One, unnamed [V]	Company release

I list only companies that put it in writing in their own release, newsroom post or investor materials. A clinic's sign-up page or a reseller's ad doesn't count here. New to how these platforms work? The telehealth clinics explainer covers the basics, and the report on FDA's 30 telehealth warning letters shows how regulators have policed online marketing so far. If I've missed a company with an official announcement, the corrections page is the place to tell me.

Is a new category forming?

Not a supplement aisle, and not an FDA-approved drug. That's the honest answer, with a gap in the middle.

What these companies are describing are compounded drugs, made by prescription at licensed pharmacies. [V] They are not dietary supplements, and they are not medicines FDA has approved for these uses. [V] Compounded drugs do not go through FDA's premarket review for safety, effectiveness or quality. [V] The HHS document on the table is a draft enforcement-discretion policy for 503A compounding of six peptides. It covers state-licensed 503A pharmacies, and it also names federal facilities and physicians who are licensed, but it is not a new official product category and not an approval. [V] It does not add those peptides to FDA's 503A bulks list. [V] That middle lane — between a supplement and an approved drug — is exactly what the November 13 comment deadline is about.

I don't know yet whether this lane holds, gets narrower, or fades. The draft can be revised, finalized or left as a draft. [V] USP, the drug-standards group, said on November 3 that the policy lacks quality safeguards it considers essential, including official standards for these substances, which the USP brief explains. [V] And none of the three companies has published how many people have actually signed up. [U]

Enhanced moved first, and fastest

Enhanced's November 3 release reads like a company that had been waiting for the starting gun. It says eligible customers can get all six peptides through licensed clinicians on Live Enhanced "beginning today," adding to the GHK-Cu and sermorelin it already offered. [V] The company describes itself as a sports competition and performance products business; it runs the Enhanced Games brand. [V]

The release lists the guardrails it says it's built in. Each of the six is prescription only, after a clinician reviews a person's health history and goals. A state-licensed U.S. pharmacy compounds each one, in the forms and routes HHS's policy allows, with a single peptide in each preparation. [V] The company says its ingredients come from FDA-registered manufacturers that follow good manufacturing practice, each with a certificate of analysis. [V] Those points track several of the ten conditions written into the HHS draft, which the November 3 explainer walks through. [U]

“Our customers have been asking for clinician-led access to these peptides.”

Maximilian Martin, Enhanced co-founder and CEO, company release, November 3, 2026

Enhanced also looked ahead. It says FDA's advisory committee is expected to review more peptides in February 2027 and that it may expand if regulators act. [V] That lines up with what FDA itself has posted: the next compounding advisory meeting is due before the end of February 2027, with GHK-Cu, dihexa and three others on the agenda. The preview of that meeting has the list. [V]

Hims is the giant, and it's taking a two-step approach

Hims & Hers reported nearly 2.8 million subscribers last quarter, so its launch is the one most likely to put these names in front of people who've never heard of them. [V] Its October 29 newsroom post previewed Peptides+ with sermorelin, glutathione, B12, NAD+ and L-carnitine, and said BPC-157 and TB-500 would follow "when allowable." [V] On the November 9 earnings call, the company narrowed the first phase to sermorelin, glutathione and NAD, arriving later this month, according to a third-party transcript. [S]

Notice what's missing from that first phase: none of the six HHS peptides. Sermorelin, glutathione and NAD each sit on older FDA compounding lists, separate from the HHS draft. [V] Hims's own CEO letter says Peptides+ comes with clinician-led plans and regular blood testing. [V] The launch story has the full picture, including the plant Hims says it bought and Andrew Huberman joining its board, and the side-by-side guide covers what the research says about the first three.

DataMEDS logged a sale, quietly

DataMEDS AI's November 9 release says Corexa Pharmacy, a subsidiary, has now sold a compounded peptide from the six for the first time, citing the HHS policy. It didn't say which peptide, at what price or how many. [V] I covered the company, its recent name change and its pharmacy network in the DataMEDS report.

Three speeds, one draft policy

Put the three side by side and you get three different reads of the same document. Enhanced is all-in on the six. DataMEDS has started small. Hims, the biggest name, is launching with ingredients that don't depend on the HHS draft at all and holding BPC-157 and TB-500 back. [V] [S] Which bet ages best depends on what happens after Thursday.

- 6days between HHS's October 28 announcement and Enhanced's November 3 launch [V]
- 2.8Msubscribers Hims reported last quarter [V]
- Nov. 13last day to comment on the HHS draft (11:59 PM ET) [V]

For tested athletes, none of this changes sport rules. BPC-157 and TB-500, for example, remain on WADA's 2026 Prohibited List, as the WADA guide explains. [S]